Core Insights - The European Commission has approved the subcutaneous formulation of Opdivo (nivolumab) for multiple solid tumor indications, making it the first PD-1 inhibitor approved for subcutaneous use in the EU [1][3]. Approval Details - The approval applies to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein [1]. - Nivolumab for subcutaneous use is co-formulated with recombinant human hyaluronidase and is indicated for various adult solid tumors, either as monotherapy or in combination with other therapies [2][4]. Clinical Study Findings - The approval was supported by data from the CheckMate -67T clinical study, which demonstrated that the subcutaneous formulation has a pharmacokinetics and safety profile comparable to the intravenous version [4]. - The study showed that the subcutaneous formulation met primary pharmacokinetic noninferiority endpoints, with a geometric mean ratio for Cavgd28 of 2.10 and for Cminss of 1.77 [7]. - The objective response rate was 24% in the subcutaneous group compared to 18% in the intravenous group, indicating comparable efficacy [7]. Market Performance - Bristol Myers' shares have declined by 17% year to date, while the industry has seen a decline of 5.4% [3].

Shares of Bristol Myers (BMY) have lost 20.7% in the past three months compared with the industry’s decline of 9.6%. The stock has also underperformed the sector and the S&P 500 during this period.While the year started on a positive note and BMY was faring well (outperforming the market), the stock has been on the downslide for the past couple of months.BMY Underperforms Industry, Sector & S&P 500 IndexImage Source: Zacks Investment ResearchEven though the first-quarter performance was better-than-expected ...

Bristol-Myers Squibb Company (NYSE:BMY) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference Call Participants Courtney Breen - Bernstein Courtney Breen Fantastic. Hi, everyone. It's great to have you here for this fireside, the first of our pharmaceutical fireside during the SDC. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein. And I am thrilled to have Chris Boerner here ...

Financial Data and Key Metrics Changes - The company reported a 16% growth in Q1, indicating a steady performance in its growth portfolio despite the decline in its legacy portfolio due to loss of exclusivity (LOE) exposure [6][10] - The company aims to achieve $2 billion in cost savings, building on the previous commitment of $1 billion announced in 2024, to enhance financial discipline and efficiency [8][42] Business Line Data and Key Metrics Changes - The late-stage pipeline is expected to deliver 15 registrational data readouts over the next 18 to 24 months, with six of these for new molecular entities [7] - The company is focusing on maintaining growth in its current portfolio while managing the decline in its legacy portfolio due to LOE [6] Market Data and Key Metrics Changes - The company is actively monitoring external pressures such as government agency changes, tariffs, and executive orders that could impact the industry [12][14] - The company has committed $40 billion in additional investments over the next five years to strengthen its position in the U.S. market [17] Company Strategy and Development Direction - The company is focused on emerging as one of the fastest-growing companies in the sector by prioritizing its growth portfolio, late-stage pipeline, and financial discipline [5][10] - The company is engaging constructively with the administration to address pricing dynamics and potential reforms in the industry [20][21] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of maintaining focus on controllable factors within the company while navigating external pressures [13][14] - The leadership team believes that operational efficiency and financial discipline will be increasingly valued in the industry moving forward [42][47] Other Important Information - The company is committed to leveraging technology and improving operational execution to enhance efficiency and agility [38][39] - The company is actively pursuing business development opportunities that align with its strategic goals and can drive growth [56][57] Q&A Session Summary Question: How does the company rank the pressures from tariffs, government changes, and other external factors? - Management stated that they prioritize controllable factors while engaging with external pressures, categorizing them into government agency changes, tariffs, and executive orders [12][14] Question: What is the company's approach to managing inventory in light of potential tariffs? - The company has taken steps to mitigate risks by bringing in products from outside the U.S. and believes the impact of tariffs will be manageable [22][23] Question: How does the company view the potential impact of drug pricing reforms? - Management acknowledged the uncertainty surrounding drug pricing reforms but emphasized the importance of engaging with the administration to find common ground [25][26] Question: What are the key strategic changes made since the new CEO took over? - The CEO highlighted the need for clarity in strategic priorities, execution consistency, and financial discipline as key focus areas for the organization [35][36] Question: How does the company plan to ensure the success of CoBINFI? - The company is focused on driving breadth and depth of use for CoBINFI, emphasizing peer-to-peer education and addressing physician concerns about switching therapies [72][74]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

It is not every day we see a picture like this. Valuation, Growth and Profitability grades from Seeking Alpha's Quant team , all standing at A+. It doesn't get any better than that for Bristol-MyersI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, and ...

For pharma stocks, it feels like depressed valuations are the new normal. Bristol-Myers Squibb (NYSE: BMY ) is a case in point - its forward price-to-earnings multiple has only turned further south since my Q3 2024 analysis. I was upbeat on shares backFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passi ...

I want to start this article by reminding you of an upcoming event that not only plays a key role and is highly valued among medical oncologists but also attracts significant interest from Wall Street.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical compan ...

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - The service offers a free two-week trial for potential investors to explore top ideas across exclusive income-focused portfolios [1] Group 2 - There are various strategies for generating significant wealth in the stock market, including early investment in high-growth stocks like Amazon and NVIDIA [2] - The focus is on defensive stocks with a medium- to long-term investment horizon [2]

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and maximize their stock market investments [1][2]. Zacks Style Scores - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum methodologies, aiding investors in selecting stocks likely to outperform the market in the short term [2][3]. - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3]. Value Score - The Value Score identifies attractive and discounted stocks using ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4]. Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [6]. Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, which has shown strong performance, with 1 (Strong Buy) stocks averaging a +25.41% annual return since 1988, significantly outperforming the S&P 500 [7][8]. - There are over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to identify the best opportunities [9]. Stock to Watch: Bristol Myers Squibb (BMY) - Bristol Myers Squibb is a leading biopharmaceutical company focused on severe disease treatments, with a strong portfolio including the immuno-oncology drug Opdivo and other essential drugs [11]. - BMY holds a 3 (Hold) Zacks Rank and a VGM Score of A, with a Value Style Score of A due to a forward P/E ratio of 6.8, making it attractive for value investors [12]. - Recent analyst revisions have increased the earnings estimate for fiscal 2025 by $0.14 to $6.89 per share, with an average earnings surprise of 20.2% [12].